Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 66.26% | 63.39% | 276.97% | 272.33% | -27.30% |
| Total Depreciation and Amortization | -78.41% | -76.51% | -173.10% | -171.12% | -6.01% |
| Total Amortization of Deferred Charges | -- | -- | -24.28% | -26.12% | -- |
| Total Other Non-Cash Items | -161.75% | -167.00% | -4,192.85% | -4,080.61% | 361.90% |
| Change in Net Operating Assets | -929.05% | -1,000.73% | -1,241.38% | -1,205.07% | 150.00% |
| Cash from Operations | 53.64% | 49.71% | -38.99% | -35.34% | -21.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 21,777.50% | 21,336.59% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 21,777.50% | 21,336.59% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 36.90% | 36.90% | 12.05% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -71.43% | -71.43% | -30.72% | -30.72% | -102.79% |
| Cash from Financing | 18.65% | 11.73% | 106.76% | 101.40% | -106.60% |
| Foreign Exchange rate Adjustments | 100.00% | 140.00% | 266.67% | 259.09% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | 20.00% | 0.00% | -20.00% |
| Net Change in Cash | 52.31% | 48.26% | 149.41% | 148.11% | -363.94% |